Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Access Clinical Trials Inc

Neither a doctor nor a teaching hospital

Research payments

$2,997,288

960 payments

Through program year 2025, Access Clinical Trials Inc is reported as receiving $2,997,288 in research payments, across 960 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $691,931 347
2024 Research $919,131 258
2023 Research $696,355 190
2022 Research $644,653 153
2021 Research $45,219 12

Breakdown

Who paid Research payments · program years 2021–2025
  1. AbbVie, Inc. $2,373,505 794 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $268,299 5 payments
  3. ITI, Inc. $216,292 122 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $65,021 23 payments
  5. Eli Lilly and Company $42,913 2 payments
  6. Biohaven Pharmaceuticals, Inc. $25,678 10 payments
  7. Pfizer Inc. $5,580 4 payments
Studies the money was for Research payments · program years 2021–2025
  1. Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $846,238 65 payments
  2. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $241,139 64 payments
  3. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $240,433 77 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder $163,544 2 payments
  5. Study of Oral Elagolix Tablets in Combination With Combined Oral Contraceptive Capsules Tablets to Assess Dysmenorrhea Response in Adult Female Participants With Endometriosis and Associated Moderate to Severe Pain $157,767 112 payments
  6. Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules;Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain $140,664 98 payments
  7. Iti-007-601 $130,105 83 payments
  8. Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine $116,832 62 payments
  9. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine $113,534 74 payments
  10. Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsulesx2FTablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain $109,006 58 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record